Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case-Control Study

Kirstine Kobberøe Søgaard; Horváth-Puhó, Erzsébet; Grønbæk, Henning; Jepsen, Peter; Vilstrup, Hendrik; Sørensen, Henrik Toft
January 2009
American Journal of Gastroenterology;Jan2009, Vol. 104 Issue 1, p96
Academic Journal
OBJECTIVES: It is known that liver disease can cause an imbalance in the coagulation system, but available data on liver disease and risk of venous thromboembolism are conflicting. We examined the risk of venous thromboembolism in patients hospitalized with liver diseases. METHODS: We conducted a nationwide Danish case-control study of incident cases of venous thromboembolism from 1980 to 2005 using population-based data from the National Registry of Patients, and from the Civil Registration System. We used conditional logistic regression to compute the relative risk of venous thromboembolism in patients with liver disease compared to population controls. We then excluded patients with known malignancy (diagnosed either before or up to 3 months after the venous thromboembolism) or fractures, trauma, surgery, or pregnancy within 90 days before the venous thromboembolism to estimate the risk associated with unprovoked venous thromboembolism. RESULTS: A total of 99,444 patients with venous thromboembolism and 496,872 population controls were included in the study. Patients with liver disease had a clearly increased relative risk of venous thromboembolism, varying from 1.74 (95% CI, 1.54-1.95) for liver cirrhosis to 1.87 (95% CI, 1.73-2.03) for non-cirrhotic liver disease. The risks were higher for deep venous thrombosis compared with pulmonary embolism. In the analysis, restricted to 67,519 patients with unprovoked venous thromboembolism and 308,614 population controls, we found slightly higher relative risks: 2.06 (95% CI, 1.79-2.38) for liver cirrhosis and 2.10 (95% CI, 1.91-2.31) for non-cirrhotic liver disease. CONCLUSIONS: Patients with liver disease have a substantially increased risk of venous thromboembolism.


Related Articles

  • No extra VTE risk with 24-day ethinylestradiol/drospirenone.  // Reactions Weekly;11/6/2010, Issue 1326, p3 

    The article reports on a study which examined the association of a 24-day contraceptive regimen comprising ethinylestradiol/drospirenone with a higher risk of venous thromboembolism (VTE).

  • The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromsø study. Blix, Kristine; Brækkan, Sigrid; Cessie, Saskia; Skjeldestad, Finn; Cannegieter, Suzanne; Hansen, John-Bjarne // European Journal of Epidemiology;Apr2014, Vol. 29 Issue 4, p277 

    Whether the high incidence of venous thromboembolism (VTE) in the elderly can be attributed to cancer is not well studied. We assessed the impact of cancer on risk of VTE in young, middle-aged and elderly. 26,094 subjects without a history of cancer or VTE were recruited from the Tromsø...

  • Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. Yun-Gyoo Lee; Eunyoung Lee; Inho Kim; Keun-Wook Lee; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Dae Seog Heo // Cancer Research & Treatment;Oct2015, Vol. 47 Issue 4, p670 

    Purpose Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated...

  • Prognostic value of mean platelet volume in patients after acute coronary syndrome. Jakl, Martin; Maly, Jaroslav // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Jan2015, Vol. 15 Issue 1, p31 

    In this article, the author discusses the association of increased mean platelet volume (MPV) with myocardial infarction. Topics discussed include risk associated with MPV such as venous thromboembolism, heart failure and diabetes mellitus, logistic regression analysis showed the independent...

  • Erythropoiesis stimulants do not reduce need for transfusions.  // Reactions Weekly;11/21/2009, Issue 1279, p5 

    The article discusses research being done on erythropoiesis stimulants. It references a study by D. L. Hershman et al published in an online issue of the "Journal of the National Cancer Institute." Findings suggest that erythropoiesis-stimulating agents do not appear to reduce the need for blood...

  • Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis. Ungprasert, Patompong; Sanguankeo, Anawin // Rheumatology International;Oct2014, Vol. 34 Issue 10, p1455 

    We performed this meta-analysis to assess venous thromboembolism risk in patients with idiopathic inflammatory myositis (IIM). A comprehensive search was performed in MEDLINE, EMBASE and the Cochrane database. Three observational studies met our inclusion criteria and were included in the data...

  • Venous Thromboembolism in Patients Having Knee Replacement and Receiving Thromboprophylaxis. Pedersen, Alma B.; Mehnert, Frank; Johnsen, Soren P.; Husted, Steen; Sorensen, Henrik T. // Journal of Bone & Joint Surgery, American Volume;7/20/2011, Vol. 93-A Issue 14, p1281 

    Background: We examined the rate of venous thromboernbolism, as well as changes overtime, in a population-based cohort of patients who underwent knee arthroplasty. Methods: Using medical databases, we identified all patients who underwent primary knee arthroplasties with phar- macological...

  • Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. Liang, Jie; Wu, Shengjun; Feng, Bin; Lei, Shaoni; Luo, Guanhong; Wang, Jingbo; Li, Kai; Li, Xiaohua; Xie, Huahong; Zhang, Dexin; Wang, Xin; Wu, Kaichun; Miao, Danmin; Fan, Daiming // Journal of Gastroenterology;Oct2011, Vol. 46 Issue 10, p1158 

    Background: Recent studies proved that inflammatory bowel disease (IBD) patients had a higher risk of thromboembolism and a Factor V Leiden mutation that prevents the efficient inactivation of factor V, which leads to thromboembolism and thus contributes to a high potential risk of IBD. However,...

  • Psoriasis and risk of venous thromboembolism: a systematic review and meta-analysis. Ungprasert, Patompong; Sanguankeo, Anawin; Upala, Sikarin; Suksaranjit, Promporn // QJM: An International Journal of Medicine;Oct2014, Vol. 107 Issue 10, p793 

    Background: Several chronic inflammatory disorders, such as rheumatoid arthritis and systemic lupus erythematosus, have been shown to increase venous thromboembolism (VTE) risk but the data on psoriasis is unclear.Methods: We conducted a systematic review and meta-analysis of observational...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics